USPTO Examiner KAUFMAN CLAIRE M - Art Unit 1646

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18612579MEMBRANE-BOUND IL-12 FOR CELLULAR IMMUNOTHERAPYMarch 2024June 2024Allow300YesNo
18394409METHODS OF TREATING A NEOPLASIA WITH IL-15-BASED MOLECULES AND CTLA-4 ANTIBODYDecember 2023June 2024Allow610YesNo
18063871METHOD OF TREATING CANCER WITH COMPOSITION COMPRISING IL-15-BASED MOLECULES AND BCGDecember 2022November 2023Allow1120NoNo
18062109BCMA TARGETTING ANTIBODIES, CHIMERIC ANTIGEN RECEPTORS, AND USES THEREOFDecember 2022March 2024Allow1521YesNo
18045572COMPOSITIONS COMPRISING IL-15-BASED MOLECULES AND IMMUNE CHECKPOINT INHIBITOR ANTIBODIESOctober 2022March 2024Allow1730YesNo
17822598ANTI-CD30L ANTIBODIES AND USES THEREOFAugust 2022August 2023Allow1211YesNo
17820682ANTI-OX40 ANTIBODY AND USES THEREOFAugust 2022February 2024Allow1821YesNo
17818840ANTI-TIGIT AND ANTI-CD96 ANTIBODIESAugust 2022March 2023Allow701YesNo
17816946METHODS OF TREATING LUPUS NEPHRITIS BY ADMINISTRAITON OF TYPE II ANTI-CD20 ANTIBODIESAugust 2022October 2024Abandon2630YesNo
17734904METHODS FOR TREATING CANCER BY ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 ANTIBODYMay 2022November 2022Allow620YesNo
17734949METHODS FOR TREATING CANCER BY ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 ANTIBODYMay 2022September 2022Allow410NoNo
17727220METHODS OF TREATMENT USING CCR8 ANTIBODIESApril 2022January 2024Allow2130YesNo
17677339ANTI-TNFRSF9 ANTIBODIES AND USES THEREOFFebruary 2022March 2024Abandon2401NoNo
17670917CD137- AND DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULESFebruary 2022December 2022Allow1010YesNo
17555282MULTIMERIC CD40 BINDING MOLECULES AND USES THEREOFDecember 2021July 2024Abandon3111NoNo
17546208METHOD OF TREATING A TUMOR USING ANTI-TfR ANTIBODIESDecember 2021March 2024Allow2711YesNo
17411953TREATMENT OF CANCER WITH DUAL TARGETING OF CD47 AND EGFRAugust 2021March 2024Allow3111YesNo
17410832TRAILshort ANTIBODY AND METHODS OF USEAugust 2021May 2024Allow3210YesNo
17394900Multivalent and Multispecific DR5-Binding Fusion Proteins and Methods of Modulating Immune CellsAugust 2021January 2024Allow2911YesNo
17358841CCR8 ANTIBODIES FOR THERAPEUTIC APPLICATIONSJune 2021February 2022Allow811YesNo
17324751ANTI-PD-1 ANTIBODIES AND USES THEREOFMay 2021February 2022Allow911YesNo
17290401BISPECIFIC ANTIBODY BINDING BCMA AND CD3April 2021February 2024Allow3410YesNo
17238842BINDING MEMBERS TO TNF ALPHAApril 2021March 2024Abandon3510NoNo
17239056TREATMENT OF CANCER WITH LARAZOTIDE DERIVATIVES IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORSApril 2021December 2021Allow810YesNo
17229303EGFR BLOCKING AGENTS FOR THE THERAPEUTIC TREATMENT OF MYOPIAApril 2021April 2024Allow3621YesNo
17216981CD3-TARGETING AND DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOFMarch 2021November 2021Allow811YesNo
17206730HUMANIZED ANTI-CD137 ANTIBODIES AND USES THEREOFMarch 2021August 2021Allow500YesNo
17200021ANTI-TNFRSF9 ANTIBODIES AND USES THEREOFMarch 2021November 2021Allow811YesNo
17193586ANTI-GITR ANTIBODIES AND USES THEREOFMarch 2021June 2023Allow2701YesNo
17193865MODIFIED T LYMPHOCYTES COMPRISING A CD52 ANTIBODY-INDUCIBLE CASPASE AND METHODS OF APOPTOSISMarch 2021July 2023Allow2800YesNo
17188025TL1A ANTIBODIES AND METHODS OF TREATMENTMarch 2021July 2023Allow2811YesNo
17165818HIGHLY POTENT ANTIBODIES BINDING TO DEATH RECEPTOR 5February 2021September 2023Allow3210YesNo
17263350METHOD FOR THE TREATMENT OF A TUMOR PATIENT WITH ADOPTIVE T CELL IMMUNOTHERAPYJanuary 2021October 2024Abandon4410NoNo
17112564Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 AntibodiesDecember 2020October 2023Allow3510YesNo
17104370High Affinity Human Antibodies to Human Angiopoietin-2November 2020October 2023Abandon3410NoNo
17102183METHODS FOR TREATING CANCER BY ACHIEVING THERAPEUTICALLY EFFECTIVE DOSES OF ANTI-CD47 ANTIBODYNovember 2020May 2021Allow610YesNo
17084881TRAILR2 CDH17 BINDING MOLECULES FOR THE TREATMENT OF CANCEROctober 2020August 2023Allow3311YesNo
17078929ANTIBODY MOLECULES TO PD-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASESOctober 2020February 2024Abandon4020NoNo
17046884ANTI-CD27 ANTIBODIES AND USE THEREOFOctober 2020June 2023Allow3211YesNo
17046671BISPECIFIC ANTIBODY WITH PROLONGED HALF-LIFE AND ENHANCED ANTI-TUMOR EFFECTOctober 2020May 2023Abandon3101NoNo
17046388ANTIBODY BINDING TIM-3 AND USE THEREOFOctober 2020June 2023Allow3311YesNo
17062100THERAPEUTIC COMPOSITIONS COMPRISING ANTI-NRP2 ANTIBODIESOctober 2020August 2023Allow3411YesNo
17062458TARGETED IL-12 HETERODIMERIC FC-FUSION PROTEINSOctober 2020August 2023Allow3411YesNo
17045143ANTI-CD27 ANTIBODIES AND USES THEREOFOctober 2020April 2024Allow4221YesNo
17037732RECOMBINANT FUSION PROTEIN AND IMMUNOGENIC COMPOSITIONSeptember 2020September 2023Abandon3510NoNo
17031615ANTIBODIES AGAINST TL1A AND USES THEREOFSeptember 2020May 2023Abandon3111NoNo
17041349ANTI-BCMA ANTIBODIES AND TREATMENT METHODSSeptember 2020January 2024Allow4021YesNo
16981321Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use ThereofSeptember 2020April 2023Abandon3110NoNo
16975137Fusion Proteins Containing CD47 Antibodies and CytokinesAugust 2020April 2023Abandon4011NoNo
16997738USE OF TLR AGONIST AND ANTI-CD47 AGENT TO ENHANCE PHAGOCYTOSIS OF CANCER CELLSAugust 2020January 2023Allow2910YesNo
16993569Single-Chain Trail-Receptor Agonist ProteinsAugust 2020October 2022Abandon2611NoNo
16969905THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1August 2020December 2023Allow4021YesNo
16986742Immune Cells Expressing Membrane-Bound Interleukin 15 (mbIL15) and Uses ThereofAugust 2020September 2022Allow2510YesNo
16966848MASKED ACTIVATABLE CD137 ANTIBODIESJuly 2020August 2023Allow3721YesNo
16965229ANTIBODY MOLECULES COMPRISING A SINGLE-DOMAIN ANTIGEN-BINDING SITE AND FAB FRAGMENTSJuly 2020April 2023Allow3321NoNo
16963595ANTI-4-1BB ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOFJuly 2020October 2022Abandon2701NoNo
16959981MULTI-SPECIFIC LIGAND BINDERSJuly 2020March 2024Allow4531YesNo
16959330Chimeric Antigen Receptor Specific for BDCA2 AntigenJune 2020May 2023Allow3520YesNo
16911052CD137 ANTIBODIES FOR T-CELL ACTIVATIONJune 2020March 2023Allow3321YesNo
16905609CHIMERIC ANTIGEN RECEPTORS COMPRISING A HUMAN TRANSFERRIN EPITOPE SEQUENCEJune 2020March 2023Allow3321NoNo
167628714-1BB ANTIBODY AND PREPARATION METHOD AND USE THEREOFJune 2020October 2022Allow2920YesNo
16771402DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES COMPRISING INTERLEUKIN RECEPTOR SIGNALING DOMAINSJune 2020December 2023Allow4221NoNo
16768447USE OF CD3XCLEC12A BISPECIFIC ANTIBODY AND IL-15 FOR COMBINATION THERAPYMay 2020September 2023Abandon4021YesNo
16768500METHODS FOR USING CD137 LIGAND AS A BIOMARKER FOR TREATMENT WITH ANTI-CD137 ANTIBODYMay 2020March 2023Abandon3411NoNo
16882800NUCLEIC ACIDS ENCODING CHIMERIC RECEPTOR COMPRISING NKP30 RECEPTOR AND CD28 AND CD3 zeta DOMAINS AND HUMAN T CELL CONTAININGMay 2020August 2023Allow3920YesNo
16877938METHOD OF USING ANTI-CD47 ANTIBODY MOLECULESMay 2020February 2022Allow2100YesNo
16876726HUMANIZED ANTIBODIES AGAINST CEACAM1May 2020August 2023Allow3921YesNo
16871799PD-L1 AND OX40 BINDING PROTEINS FOR CANCER REGULATIONMay 2020December 2022Allow3121NoNo
16335971BINDING MOLECULES THAT BIND CD137 AND PD-L1May 2020November 2022Allow4411YesNo
16866425SIRP-GAMMA POLYPEPTIDE COMPOSITIONS AND METHODS OF USEMay 2020May 2022Allow2410YesNo
16760600CD137 ANTIBODIES AND PD-1 ANTAGONISTS AND USES THEREOFApril 2020February 2023Allow3421YesNo
16760681TRIPLE-CHAIN ANTIBODY, METHOD FOR PREPARATION AND USE THEREOFApril 2020June 2023Abandon3811NoNo
16760180CRTAM ANTIBODIES AND METHODS OF TREATING CANCERApril 2020February 2023Allow3420YesNo
16759722ANTI-LAG-3 ANTIBODY AND USE THEREOFApril 2020March 2023Allow3521NoNo
16857573POLYNUCLEOTIDES ENCODING RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORSApril 2020September 2023Allow4121YesNo
16610919CEA.CAR-T, PREPARATION METHOD THEREFOR AND USE THEREOFApril 2020January 2023Abandon3901NoNo
16755091MODULATING THE IMMUNE RESPONSE USING ANTIBODY-DRUG CONJUGATESApril 2020January 2023Abandon3420NoNo
16844747KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY G MEMBER 1 (KLRG1) DEPLETING ANTIBODIESApril 2020July 2021Allow1511YesNo
16753876ANTIBODIES TARGETING PDL1 AND METHODS OF USE THEREOFApril 2020April 2024Allow4940YesNo
16841306ANTI-DR5 FAMILY ANTIBODIES, BISPECIFIC OR MULTIVALENT ANTI-DR5 FAMILY ANTIBODIES AND METHODS OF USE THEREOFApril 2020December 2023Abandon4430NoNo
16830322LRP5 AND PD-1 ANTAGONIST ANTICANCER COMBINATION THERAPYMarch 2020November 2022Allow3221YesNo
16825773COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTSMarch 2020April 2023Abandon3712NoNo
16648731AGONISTIC CD40 ANTIBODIESMarch 2020February 2023Allow3521YesNo
16647973ANTI-YKL40 ANTIBODIES AND METHODS OF USEMarch 2020March 2023Abandon3521YesNo
16807539Method Treating Malignant Ascites and Metastatic Pleural Effusion with and Disulfide-Linked Trimeric TRAILMarch 2020June 2022Allow2820YesNo
16803126Method for Treating Cancer Using Disulfide-Linked Trimeric 4-1BBLFebruary 2020April 2022Allow2610YesNo
16642001TP53 AS BIOMARKER FOR RESPONSIVENESS TO IMMUNOTHERAPYFebruary 2020November 2022Abandon3301NoNo
16798030MITIGATION AND REVERSAL OF INTESTINAL FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTIONFebruary 2020April 2022Allow2610YesNo
16640684METHOD FOR TREATING CANCER USING ANTI-CD137 ANTIBODYFebruary 2020July 2023Allow4131YesNo
16637524Cells Expressing Cell Surface Receptors and AntibodiesFebruary 2020January 2023Abandon3601NoNo
16750842ANTI-CD137 ANTIBODIESJanuary 2020July 2022Allow3011YesNo
16631961PHOSPHATIDYLSERINE TARGETING FUSION MOLECULES AND METHODS FOR THEIR USEJanuary 2020February 2022Allow2521YesNo
16737503TREATMENT OF SKIN DISORDERS WITH COMPOSITIONS COMPRISING AN EGFR INHIBITORJanuary 2020December 2022Allow3531NoNo
16626991ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINSDecember 2019February 2024Abandon4921NoNo
16626060MONOCLONAL ANTIBODY TARGETING HUMAN TUMOR STEM CELLS AND USE THEREOFDecember 2019March 2023Allow3811YesNo
16721485BAFF-R BISPECIFIC T-CELL ENGAGER ANTIBODYDecember 2019May 2024Abandon5341NoNo
16619891A COMBINATION OF, OR A BISPECIFIC BINDING MOLECULE TO, AN IMMUNE CHECKPOINT MOLECULE ANTAGONIST AND A RANK-L (NF-KB LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOFDecember 2019January 2024Abandon4911NoNo
16618722THERAPEUTIC ANTIBODIES BASED ON MUTATED IGG HEXAMERSDecember 2019December 2022Abandon3711NoNo
16700490POLYNUCLEOTIDES ENCODING HUMANIZED ANTIBODIES AGAINST CEACAM1December 2019May 2022Allow2900YesNo
16698701NOVEL ADMINISTRATION ROUTES FOR IMMUNE AGONISTSNovember 2019September 2023Abandon4520NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KAUFMAN, CLAIRE M.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
3
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.7%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
66
Allowed After Appeal Filing
8
(12.1%)
Not Allowed After Appeal Filing
58
(87.9%)
Filing Benefit Percentile
12.5%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 12.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner KAUFMAN, CLAIRE M - Prosecution Strategy Guide

Executive Summary

Examiner KAUFMAN, CLAIRE M works in Art Unit 1646 and has examined 582 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner KAUFMAN, CLAIRE M's allowance rate of 50.0% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by KAUFMAN, CLAIRE M receive 1.64 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by KAUFMAN, CLAIRE M is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +60.9% benefit to allowance rate for applications examined by KAUFMAN, CLAIRE M. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.5% of applications are subsequently allowed. This success rate is in the 31% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 50.3% of cases where such amendments are filed. This entry rate is in the 71% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 87.5% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 90.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 53.0% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.4% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.5% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.